Barr confirms UROXATRAL patent challenge Barr Pharmaceuticals, Inc. Offers verified that its subsidiary, Barr Laboratories, Inc., offers initiated a problem of the patents detailed by Sanofi – Aventis U.S. LLC regarding the its UROXATRAL , 10mg. Barr’s Abbreviated New Medication Application including a paragraph IV qualification for a generic UROXATRAL item was received as suitable for submitting by the U.S. Food & Medication Administration on June 12, 2007, the initial time the FDA could acknowledge an ANDA with a paragraph IV certification because of this product. Pursuing receipt of the see from the FDA that Barr’s ANDA have been accepted for submitting, Barr notified the brand new Drug Program and patent holder.Financial Review ————— – Total revenue in ’09 2009 was $3.2 million, weighed against $1.5 million in 2008. Revenue from Lipofen totalled $2.9 million in 2009 2009, reflecting the continued market penetration by Lipofen as Kowa increases the sales and advertising effort behind the merchandise. Revenue from CIP-ISOTRETINOIN was $0.3 million in 2009 2009, which relates to revenue recognized on the Company’s talk about of the US$1 million upfront milestone payment received from Ranbaxy in 2008. Gross Research and Advancement expenditures for 2009 were $5.4 million, compared with $2.2 million in 2008.